Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients

Author(s): Tamer A. Elbedewy, Hossam Eldin A. Elashtokhy, Sherief Abd-Elsalam* and Marwa A. Suliman

Volume 20, Issue 8, 2020

Page: [638 - 645] Pages: 8

DOI: 10.2174/1568009620666200511084731

Price: $65

Abstract

Background: Egypt is one of the highest hepatitis C virus (HCV) endemic areas. Chronic HCV infection has extra-hepatic manifestations, including non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is commonly associated with HCV infection. The prognostic value of HCV infection and HCV treatment in patients with DLBCL remains unclear until now.

Objective: The aim of our study is to evaluate the impact of HCV infection and HCV treatment as independent prognostic factors on the event-free survival (EFS) and overall survival (OS) in Egyptian patients with HCV associated DLBCL.

Methods: This study included 353 patients with DLBCL, collected retrospectively. While 34 patients with HCV who received HCV antiviral therapy were collected prospectively. Patient’s characteristics were collected from the patient records at the time of diagnosis. The status of the patients about HCV infection and HCV treatment were also recorded. Disease progression, relapse, retreatment or deaths were also verified through medical records. EFS and OS were calculated.

Results: EFS and OS significantly decrease in HCV infected and HCV non-treated patients when compared with HCV non-infected and HCV treated patients, respectively. HCV infection but not HCV treatment was independently associated with EFS and OS using univariate and multivariate analysis.

Conclusion: Hepatitis C virus infection is an independent prognostic factor for EFS and OS in diffuse large B-cell lymphoma. HCV treatment is associated with higher EFS and OS but can not be considered as an independent prognostic factor.

Keywords: Diffuse large B-cell lymphoma, HCV, viral hepatitis, survival, cancer, prognosis.

« Previous
Graphical Abstract

[1]
Ghany, M.G.; Strader, D.B.; Thomas, D.L.; Seeff, L.B. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology, 2009, 49(4), 1335-1374.
[http://dx.doi.org/10.1002/hep.22759] [PMID: 19330875]
[2]
Gower, E.; Estes, C.; Blach, S.; Razavi-Shearer, K.; Razavi, H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol., 2014, 61(1)(Suppl.), S45-S57.
[http://dx.doi.org/10.1016/j.jhep.2014.07.027] [PMID: 25086286]
[3]
Waked, I.; Doss, W.; El-Sayed, M.H.; Estes, C.; Razavi, H.; Shiha, G.; Yosry, A.; Esmat, G. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J. Gastroenterol., 2014, 15(2), 45-52.
[http://dx.doi.org/10.1016/j.ajg.2014.04.003] [PMID: 25097045]
[4]
Ahmed, O.A.; Kaisar, H.H.; Badawi, R.; Hawash, N.; Samir, H.; Shabana, S.S.T.; Fouad, M.H.A.; Rizk, F.H.; Khodeir, S.A.; Abd-Elsalam, S. Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect. Drug Resist., 2018, 11, 295-298.
[http://dx.doi.org/10.2147/IDR.S153060] [PMID: 29535545]
[5]
Abdelmoemen, G.; Khodeir, S.A.; Abou-Saif, S.; Kobtan, A.; Abd-Elsalam, S. Prevalence of occult hepatitis C virus among hemodialysis patients in Tanta University Hospitals: A single-center study. Environ. Sci. Pollut. Res. Int., 2018, 25(6), 5459-5464.
[http://dx.doi.org/10.1007/s11356-017-0897-y] [PMID: 29214477]
[6]
Cacoub, P.; Poynard, T.; Ghillani, P.; Charlotte, F.; Olivi, M.; Piette, J.C.; Opolon, P. MULTIVIRC Group Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment virus C. Arthritis Rheum., 1999, 42(10), 2204-2212.
[http://dx.doi.org/10.1002/1529-0131(199910)42:10<2204:AID-ANR24>3.0.CO;2-D] [PMID: 10524695]
[7]
Dal Maso, L.; Franceschi, S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol. Biomarkers Prev., 2006, 15(11), 2078-2085.
[http://dx.doi.org/10.1158/1055-9965.EPI-06-0308] [PMID: 17119031]
[8]
Ennishi, D.; Maeda, Y.; Niitsu, N.; Kojima, M.; Izutsu, K.; Takizawa, J.; Kusumoto, S.; Okamoto, M.; Yokoyama, M.; Takamatsu, Y.; Sunami, K.; Miyata, A.; Murayama, K.; Sakai, A.; Matsumoto, M.; Shinagawa, K.; Takaki, A.; Matsuo, K.; Kinoshita, T.; Tanimoto, M. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: A Japanese multicenter analysis. Blood, 2010, 116(24), 5119-5125.
[http://dx.doi.org/10.1182/blood-2010-06-289231] [PMID: 20823454]
[9]
Cowgill, K.D.; Loffredo, C.A.; Eissa, S.A.; Mokhtar, N. Abdel-Hamid, M.; Fahmy, A.; Strickland, G.T. Case-control study of non-Hodgkin’ lymphoma and hepatitis C virus infection in Egypt. Int. J. Epidemiol., 2004, 33(5), 1034-1039.
[http://dx.doi.org/10.1093/ije/dyh183] [PMID: 15155696]
[10]
Youssef, S.S.; Nasr, A.S.; El Zanaty, T.; El Rawi, R.S.; Mattar, M.M. Prevalence of occult hepatitis C virus in egyptian patients with chronic lymphoproliferative disorders. Hepat. Res. Treat., 2012.2012429784
[http://dx.doi.org/10.1155/2012/429784] [PMID: 23304473]
[11]
Abu-Taleb, F.; El-Hefni, A.; Kotb, A.; El-Gohary, T.A. Efficacy of ribavirin to prevent hepatitis reactivation in hepatitis C virus infected patients treated for non-Hodgkin lymphoma. Afro-Egypt J. Infect. Endem. Dis., 2013, 3(1), 17-26.
[http://dx.doi.org/10.21608/aeji.2013.17092]
[12]
Hartridge-Lambert, S.K.; Stein, E.M.; Markowitz, A.J.; Portlock, C.S. Hepatitis C and non-Hodgkin lymphoma: The clinical perspective. Hepatology, 2012, 55(2), 634-641.
[http://dx.doi.org/10.1002/hep.25499] [PMID: 22120959]
[13]
Besson, C.; Canioni, D.; Lepage, E.; Pol, S.; Morel, P.; Lederlin, P. Groupe d’Etude des Lymphomes de l’Adulte Programs. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Grouped’Etude des Lymphomes de l’Adulte programs. J. Clin. Oncol., 2006, 24(6), 953-960.
[http://dx.doi.org/10.1200/JCO.2005.01.5016] [PMID: 16418500]
[14]
Visco, C.; Arcaini, L.; Brusamolino, E.; Burcheri, S.; Ambrosetti, A.; Merli, M.; Bonoldi, E.; Chilosi, M.; Viglio, A.; Lazzarino, M.; Pizzolo, G.; Rodeghiero, F. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: Analysis of 156 patients from northern Italy. Ann. Oncol., 2006, 17(9), 1434-1440.
[http://dx.doi.org/10.1093/annonc/mdl131] [PMID: 16766591]
[15]
Harris, N.L. Principles of the revised European–American lymphoma classification (from the International Lymphoma Study Group). Ann. Oncol., 1997, 8(Suppl. 2), 11-16.
[http://dx.doi.org/10.1093/annonc/8.suppl_2.S11] [PMID: 9209633]
[16]
Cheson, B.D.; Horning, S.J.; Coiffier, B.; Shipp, M.A.; Fisher, R.I.; Connors, J.M.; Lister, T.A.; Vose, J.; Grillo-López, A.; Hagenbeek, A.; Cabanillas, F.; Klippensten, D.; Hiddemann, W.; Castellino, R.; Harris, N.L.; Armitage, J.O.; Carter, W.; Hoppe, R.; Canellos, G.P. NCI Sponsored International Working Group Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J. Clin. Oncol., 1999, 17(4), 1244.
[http://dx.doi.org/10.1200/JCO.1999.17.4.1244] [PMID: 10561185]
[17]
Mohamed, A.A.; El-Toukhy, N.E.R.; Said, E.M.; Gabal, H.M.R.; AbdelAziz, H.; Doss, W.; El-Hanafi, H.; El Deeb, H.H.; Mahmoud, S.; Elkadeem, M.; Shalby, H.S.; Abd-Elsalam, S. Hepatitis C virus: Efficacy of new DAAs Regimens. Infect. Disord. Drug Targets, 2019.
[http://dx.doi.org/10.2174/1871526519666190121114003] [PMID: 30663575]
[18]
Park, B.B.; Kim, J.S.; Lee, Y.Y.; Kang, H.J.; Ryoo, B.Y.; Kang, J.H.; Kim, H.Y.; Kim, B.S.; Oh, S.Y.; Kwon, H.C.; Won, J.H.; Kim, K.; Park, K.; Suh, C.; Kim, W.S. Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. Leuk. Lymphoma, 2008, 49(1), 88-94.
[http://dx.doi.org/10.1080/10428190701732861] [PMID: 18203017]
[19]
Nishikawa, H.; Tsudo, M.; Osaki, Y. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: A single center experience. Oncol. Rep., 2012, 28(3), 835-840.
[http://dx.doi.org/10.3892/or.2012.1883] [PMID: 22736295]
[20]
Chen, Y.Y.; Huang, C.E.; Liang, F.W.; Lu, C.H.; Chen, P.T.; Lee, K.D.; Chen, C.C. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index. Cancer Epidemiol., 2015, 39(3), 382-387.
[http://dx.doi.org/10.1016/j.canep.2015.04.004] [PMID: 25899771]
[21]
Dlouhy, I.; Torrente, M.Á.; Lens, S.; Rovira, J.; Magnano, L.; Giné, E.; Delgado, J.; Balagué, O.; Martínez, A.; Campo, E.; Forns, X.; Sánchez-Tapias, J.M.; López-Guillermo, A. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Ann. Hematol., 2017, 96(3), 405-410.
[http://dx.doi.org/10.1007/s00277-016-2903-8] [PMID: 28035434]
[22]
Tsutsumi, Y.; Nakayama, C.; Kamada, K.; Kikuchi, R.; Kudo, D.; Ito, S.; Matsuoka, S.; Shiratori, S.; Yamamoto, Y.; Naruse, H.; Teshima, T. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma. Ann. Hematol., 2017, 96(12), 2057-2061.
[http://dx.doi.org/10.1007/s00277-017-3129-0] [PMID: 28939993]
[23]
Tsutsumi, Y.; Ito, S.; Ogasawara, R.; Kudo, K.; Tanaka, J.; Asaka, M.; Imamura, M. HCV virus and lymphoid neoplasms. Adv. Hematol., 2011.2011717951
[http://dx.doi.org/10.1155/2011/717951] [PMID: 21747860]
[24]
Hosry, J.; Mahale, P.; Turturro, F.; Miranda, R.N.; Economides, M.P.; Granwehr, B.P.; Torres, H.A. Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. Int. J. Cancer, 2016, 139(11), 2519-2528.
[http://dx.doi.org/10.1002/ijc.30372] [PMID: 27501007]
[25]
Chen, T.T.; Chiu, C.F.; Yang, T.Y.; Lin, C.C.; Sargeant, A.M.; Yeh, S.P.; Liao, Y.M.; Bai, L.Y. Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy. Leuk. Res., 2015b, 39(2), 151-156.
[http://dx.doi.org/10.1016/j.leukres.2014.11.015] [PMID: 25524176]
[26]
Arcaini, L.; Vallisa, D.; Rattotti, S.; Ferretti, V.V.; Ferreri, A.J.; Bernuzzi, P.; Merli, M.; Varettoni, M.; Chiappella, A.; Ambrosetti, A.; Tucci, A.; Rusconi, C.; Visco, C.; Spina, M.; Cabras, G.; Luminari, S.; Tucci, M.; Musto, P.; Ladetto, M.; Merli, F.; Stelitano, C.; d’Arco, A.; Rigacci, L.; Levis, A.; Rossi, D.; Spedini, P.; Mancuso, S.; Marino, D.; Bruno, R.; Baldini, L.; Pulsoni, A. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann. Oncol., 2014, 25(7), 1404-1410.
[http://dx.doi.org/10.1093/annonc/mdu166] [PMID: 24799461]
[27]
Merli, M.; Carli, G.; Arcaini, L.; Visco, C. Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. World J. Gastroenterol., 2016, 22(38), 8447-8458.
[http://dx.doi.org/10.3748/wjg.v22.i38.8447] [PMID: 27784957]
[28]
Hermine, O.; Lefrère, F.; Bronowicki, J.P.; Mariette, X.; Jondeau, K.; Eclache-Saudreau, V.; Delmas, B.; Valensi, F.; Cacoub, P.; Brechot, C.; Varet, B.; Troussard, X. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N. Engl. J. Med., 2002, 347(2), 89-94.
[http://dx.doi.org/10.1056/NEJMoa013376] [PMID: 12110736]
[29]
Sultanik, P.; Klotz, C.; Brault, P.; Pol, S.; Mallet, V. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood, 2015, 125(15), 2446-2447.
[http://dx.doi.org/10.1182/blood-2014-12-618652] [PMID: 25858892]
[30]
Economides, M.P.; Mahale, P.; Kyvernitakis, A.; Turturro, F.; Kantarjian, H.; Naing, A.; Hosry, J.; Shigle, T.L.; Kaseb, A.; Torres, H.A. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment. Pharmacol. Ther., 2016, 44(11-12), 1235-1241.
[http://dx.doi.org/10.1111/apt.13825] [PMID: 27730654]
[31]
Torres, H.A.; Shigle, T.L.; Hammoudi, N.; Link, J.T.; Samaniego, F.; Kaseb, A.; Mallet, V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J. Clin., 2017, 67(5), 411-431.
[http://dx.doi.org/10.3322/caac.21403] [PMID: 28683174]
[32]
Michot, J.M.; Canioni, D.; Driss, H.; Alric, L.; Cacoub, P.; Suarez, F.; Sibon, D.; Thieblemont, C.; Dupuis, J.; Terrier, B.; Feray, C.; Tilly, H.; Pol, S.; Leblond, V.; Settegrana, C.; Rabiega, P.; Barthe, Y.; Hendel-Chavez, H.; Nguyen-Khac, F.; Merle-Béral, H.; Berger, F.; Molina, T.; Charlotte, F.; Carrat, F.; Davi, F.; Hermine, O.; Besson, C. ANRS HC-13 Lympho-C Study Group. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am. J. Hematol., 2015, 90(3), 197-203.
[http://dx.doi.org/10.1002/ajh.23889] [PMID: 25417909]

Rights & Permissions Print Cite
Article Metrics
10
2
© 2024 Bentham Science Publishers | Privacy Policy